Technology is advancing at a sky-rocketing pace. Here’s an interesting wound management solution by EnzySurge. The company recently revealed a novel therapeutic method called SilverStream that can be used for the treatment of pressure ulcers, diabetic ulcers, post-surgical wounds and first and second degree burns. The solution has received the U.S. Food and Drug Administration (FDA) clearance.
Now available for prescription use, the company also shares the clearance of DermaSept which is an over-the-counter version of the SilverStream product. The new SilverStream solution will feature in the DermaStream is a line of wound care devices. This portfolio allows the continuous streaming of fresh therapeutic solutions like SilverStream, over the wound bed. Offering constant removal of foreign material, the treatment claims to help exudate, micro-organisms and debris and also appears to create negative pressure over the wound.
SilverStream can be administered either directly onto the wound or through the disposable DermaStream device. Dr. Noa Hadar and Prof. Amihay Freeman who led the development elucidate the product to be a hypertonic solution comprising of a very low concentration of preservative silver ions. It has been designed for use under the supervision of a healthcare professional.
“SilverStream has demonstrated remarkable capabilities by in-vitro testing inhibiting the growth of drug-resistant clinical bacterial strains, yeast and fungi upon contact in-vitroâ€, revealed Freeman.
“We are extremely pleased to receive FDA clearance for this unique productâ€, adds Amir Shiner Chief Executive Officer of EnzySurge. “We believe that SilverStream is a powerful wound management solution and will be a significant addition to the DermaStream product line, which is intended to become the wound management system of choice. We are poised to launching SilverStream to market in 2010 with our U.S. partner, the Virginia Biosciences Commercialization Center.â€
SilverStream appears to have the ability to manage and moisturize wounds like stage I-IV pressure ulcers, stasis ulcers, diabetic foot ulcers, post-surgical wounds, first and second degree burns, cuts abrasions and minor skin irritations. As for DermaSept, it is aimed at the management and moisturizing of minor cuts, minor burns, abrasions and irritated areas.
This new product should find a key place in the treatment of chronic wounds like such as diabetic, pressure and venous ulcers that are claimed to not only be expensive and laborious but also needs continuous application and monitoring by a skilled caregiver.
